Androgen therapy in the aging male

Area of Science:

• Endocrinology
• Gerontology
• Men's Health

Background:

• Global population aging and increased life expectancy highlight the growing aging male demographic.
• Aging males experience significant endocrine changes, including reduced hormone production and dampened circadian rhythms.
• These changes contribute to age-dependent decreases in testosterone, dehydroepiandrosterone (DHEA), thyroid hormones, growth hormone (GH), IGF1, and melatonin.

Purpose of the Study:

• To review the diagnosis and management of late-onset hypogonadism in aging men.
• To discuss the role of hormone therapies, particularly testosterone therapy (HT), in addressing age-related endocrine deficiencies.
• To provide recommendations for diagnostic algorithms and therapy monitoring for late-onset hypogonadism.

Main Methods:

• Comprehensive review of existing literature on aging, endocrinology, and hormone replacement therapy.
• Analysis of prospective studies on testosterone therapy in aging males.
• Evaluation of diagnostic criteria and monitoring strategies for late-onset hypogonadism.

Main Results:

• Late-onset hypogonadism is a syndrome associated with aging, characterized by hypogonadism signs, symptoms, and low androgen levels.
• Hormone therapies, including testosterone therapy, show potential benefits in preventing or delaying certain aspects of aging in select older men.
• Evidence for testosterone therapy in aging males is evolving, with prospective studies indicating benefits for specific conditions.

Conclusions:

• Hormonal changes are integral to male aging, potentially leading to late-onset hypogonadism and reduced quality of life.
• Accurate diagnosis requires a thorough medical history, physical examination, and laboratory testing, considering co-existing conditions.
• Testosterone therapy can be beneficial for certain aging men, necessitating evidence-based guidelines for diagnosis and monitoring.